Phase 4
N=88
Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression
Depression
Bottom Line
View on ClinicalTrials.gov: NCT00200902 ↗Enrolled (actual)
88
Serious AEs
0.0%
Results posted
Apr 2019
Primary outcome: Primary: Response as Assessed by Participants' Change in Depression Rating — 17; 11; 1; 9 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro) (Drug); Placebo (Other); Interpersonal Clinical Interaction (ICI) (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of California, Los Angeles
- Primary completion
- Jun 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Response as Assessed by Participants' Change in Depression Rating |
17; 11; 1; 9; 9; 0 | — |
| PRIMARY Average Change in 3 Weeks of Participant Treatment Expectations |
3.55; 3.94; 3.17 | — |
| PRIMARY Change in Hamilton Depression Assessment Score |
-0.46; -0.36; -0.05; -10.05; -7.59; -1.37 | — |
Summary
This study will use measurements of depression symptoms and brain activity to determine what factors may influence an individual's response to treatment for depression.
Eligibility Criteria
Inclusion Criteria
- Clinical diagnosis of unipolar major depression
Exclusion Criteria
- Substance abuse
- Psychotic disorder
- History of severe head trauma
Data sourced from ClinicalTrials.gov (NCT00200902). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.